Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee
Executive Summary
FDA seems content to negotiate a user fee for biosimilars in a manner that typifies the composition of the products: similar, but not the same, as the other user fee programs.
You may also be interested in...
Biosimilar User Fee Negotiations Won't Start Until 2016
Mid-December kick-off meeting puts emerging user fee program on much later track than others.
User Fee Conference Committee Targets Settling Differences In June
A conference committee tackles differences between House and Senate FDA user fee and agency reform bills, with an agreement expected before the end of June.
User Fee Conference Committee Targets Settling Differences In June
A conference committee tackles differences between House and Senate FDA user fee and agency reform bills, with an agreement expected before the end of June.